Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy

G. Filaci, M. Cutolo, M. Scudeletti, C. Castagneto, L. Derchi, R. Gianrossi, F. Ropolo, P. Zentilin, A. Sulli, G. Murdaca, M. Ghio, F. Indiveri, F. Puppo

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives. The main aim was to analyse the long-term therapeutic effects on systemic sclerosis (SSc) patients of treatment with either (i) iloprost alone or (ii) low-dose oral cyclosporin A (CyA) associated with iloprost. A secondary aim was to analyse interleukin-6 (IL-6) serum levels in SSc patients before and after 1 yr of treatment. Methods. A clinical trial was performed in which 20 consecutive SSc patients were alternately randomized into two homogeneous groups receiving either monthly i.v. iloprost (1 ng/kg/min in 6 h i.v. infusion, for 5 consecutive days, 1 week per month) (Group I) or low-dose CyA (2.5 mg/kg/day) associated with iloprost administration (Group II). IL-6 concentrations were evaluated by ELISA in the sera of each patient before and after 1 yr of therapy and in 20 healthy subjects. Results. After 1 yr of therapy, a significant improvement of skin (P = 0.008), microvascular (P = 0.004) and oesophageal (P = 0.05) morphological and functional parameters was observed only in Group II patients. Furthermore, after 1 yr of treatment, a significant reduction (P = 0.007) of IL-6 serum concentration was observed only in Group II patients. Conclusions. Collectively, our data suggest that the combination of low-dose CyA with iloprost administration may be of clinical utility in SSc and that a mechanism of action of CyA in SSc may include the decrease in IL-6 production.

Original languageEnglish
Pages (from-to)992-996
Number of pages5
JournalRheumatology
Volume38
Issue number10
DOIs
Publication statusPublished - Oct 1999

Keywords

  • Cyclosporin A
  • Iloprost
  • Interleukin 6
  • Systemic sclerosis

ASJC Scopus subject areas

  • Neuroscience(all)
  • Rheumatology

Fingerprint

Dive into the research topics of 'Cyclosporin A and iloprost treatment of systemic sclerosis: Clinical results and interleukin-6 serum changes after 12 months of therapy'. Together they form a unique fingerprint.

Cite this